Comparative Pharmacology
Head-to-head clinical analysis: FABRAZYME versus LUMIZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABRAZYME versus LUMIZYME.
FABRAZYME vs LUMIZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
5 mg/kg administered intravenously once every 2 weeks.
None Documented
None Documented
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy